158 related articles for article (PubMed ID: 29661415)
1. Reversal of dabigatran by intraosseous or intravenous idarucizumab in a porcine polytrauma model.
Akman N; Braunschweig T; Honickel M; Schütt K; Schöchl H; Stoppe C; Rossaint R; Grottke O
Br J Anaesth; 2018 May; 120(5):978-987. PubMed ID: 29661415
[TBL] [Abstract][Full Text] [Related]
2. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
[TBL] [Abstract][Full Text] [Related]
3. Reversing Dabigatran Anticoagulation with Prothrombin Complex Concentrate versus Idarucizumab as Part of Multimodal Hemostatic Intervention in an Animal Model of Polytrauma.
Honickel M; Braunschweig T; Rossaint R; Stoppe C; Ten Cate H; Grottke O
Anesthesiology; 2017 Nov; 127(5):852-861. PubMed ID: 28857806
[TBL] [Abstract][Full Text] [Related]
4. Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
Honickel M; Spronk HM; Rossaint R; Stoppe C; van Ryn J; Ten Cate H; Grottke O
Thromb Haemost; 2017 Jun; 117(7):1370-1378. PubMed ID: 28424818
[TBL] [Abstract][Full Text] [Related]
5. Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model.
Honickel M; Maron B; van Ryn J; Braunschweig T; ten Cate H; Spronk HM; Rossaint R; Grottke O
Thromb Haemost; 2016 Jan; 115(2):271-84. PubMed ID: 26333775
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
[TBL] [Abstract][Full Text] [Related]
7. Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report.
Tireli D; He J; Nordling MM; Wienecke T
J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):e123-e125. PubMed ID: 28479184
[TBL] [Abstract][Full Text] [Related]
8. Idarucizumab: A Review as a Reversal Agent for Dabigatran.
Syed YY
Am J Cardiovasc Drugs; 2016 Aug; 16(4):297-304. PubMed ID: 27388764
[TBL] [Abstract][Full Text] [Related]
9. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
Thibault N; Morrill AM; Willett KC
Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
[TBL] [Abstract][Full Text] [Related]
10. Idarucizumab: First Global Approval.
Burness CB
Drugs; 2015 Dec; 75(18):2155-61. PubMed ID: 26578027
[TBL] [Abstract][Full Text] [Related]
11. Prothrombin Complex Concentrate Is Effective in Treating the Anticoagulant Effects of Dabigatran in a Porcine Polytrauma Model.
Honickel M; Braunschweig T; van Ryn J; Ten Cate H; Spronk HM; Rossaint R; Grottke O
Anesthesiology; 2015 Dec; 123(6):1350-61. PubMed ID: 26414500
[TBL] [Abstract][Full Text] [Related]
12. Idarucizumab for Dabigatran Reversal.
Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
[TBL] [Abstract][Full Text] [Related]
13. Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.
Glund S; Stangier J; van Ryn J; Schmohl M; Moschetti V; Haazen W; De Smet M; Gansser D; Norris S; Lang B; Reilly P; Kreuzer J
Clin Pharmacokinet; 2017 Jan; 56(1):41-54. PubMed ID: 27317414
[TBL] [Abstract][Full Text] [Related]
14. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
Sié P
Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
[TBL] [Abstract][Full Text] [Related]
15. Idarucizumab, a Specific Dabigatran Reversal Agent, Reduces Blood Loss in a Porcine Model of Trauma With Dabigatran Anticoagulation.
Grottke O; Honickel M; van Ryn J; ten Cate H; Rossaint R; Spronk HM
J Am Coll Cardiol; 2015 Sep; 66(13):1518-9. PubMed ID: 26403349
[No Abstract] [Full Text] [Related]
16. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.
Glund S; Moschetti V; Norris S; Stangier J; Schmohl M; van Ryn J; Lang B; Ramael S; Reilly P
Thromb Haemost; 2015 May; 113(5):943-51. PubMed ID: 25789661
[TBL] [Abstract][Full Text] [Related]
17. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
[TBL] [Abstract][Full Text] [Related]
18. Reversal of dabigatran by idarucizumab: when and how?
Vanassche T; Greinacher A; Verhamme P
Expert Rev Hematol; 2016 Jun; 9(6):519-28. PubMed ID: 27166653
[TBL] [Abstract][Full Text] [Related]
19. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
Yogaratnam D; Ditch K; Medeiros K; Doyno C; Fong JJ
Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
[TBL] [Abstract][Full Text] [Related]
20. Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran.
Miyares MA; Kuyumjian Y; Eaves S; Dollard E
J Pharm Pract; 2015 Dec; 28(6):548-54. PubMed ID: 26894245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
